newsfilter
← Latest News
Business Wire·

2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies

Initial MAGE-A4 T-cell collaboration program set to enter clinic ahead of schedule by end of 2023 Companies plan to add programs in oncology and autoimmune disease to collaboration 2seventy bio, Inc. (NASDAQ:TSVT),